Carregant...
Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer
This phase II trial tested the rate of pathologic complete response (pCR) achieved by women with stage II–III human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer (BC) treated with neo-adjuvant nanoparticle albumin-bound paclitaxel (nab-P), carboplatin and bevacizumab. The...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4104207/ https://ncbi.nlm.nih.gov/pubmed/24703985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2014.02.005 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|